GE HealthCare Introduces Caption AI on Vscan Air SL Wireless Handheld Ultrasound System to Help More Clinicians Capture Diagnostic-Quality Cardiac Images
April 03 2024 - 8:00AM
Business Wire
- Caption AI on Vscan Air SL expands access to cardiac care by
enabling more medical professionals to feel confident acquiring
images for rapid assessments
- AutoEF feature automatically calculates ejection fraction,
saving time for clinicians while delivering key information for
making their diagnoses
- GE HealthCare to debut new technology at 2024 American College
of Cardiology Annual Scientific Session & Expo, April 6 – 8,
2024 in Atlanta
GE HealthCare (Nasdaq: GEHC) today announced the launch of
Caption AI artificial intelligence (AI)-driven software for rapid
cardiac assessments at the point of care on Vscan Air SL. Now, with
Caption AI technology, clinicians using Vscan Air SL handheld
ultrasound will have access to real-time, step-by-step guidance to
capture diagnostic-quality images and automated ejection fraction
estimation to help inform clinical decisions across cardiac
settings. Vscan Air SL with Caption AI will debut at the 2024
American College of Cardiology (ACC) Annual Scientific Session
& Expo, taking place April 6 – 8, 2024 in Atlanta.
Cardiovascular disease (CVD) is the leading cause of death
globally, and the prevalence is expected to continue rising as
people live longer and the population increases.1 Early detection
of heart disease is critical to improving patient outcomes, but
providing rapid echocardiographic assessments at the point of care
can be difficult in resource-constrained facilities and practices.
Vscan Air SL with Caption AI is designed to lower the threshold for
healthcare professionals to be able to capture cardiac images so
that even non-expert ultrasound users can take a quick look at
patients’ hearts.
"With the increase of cardiovascular disease and shortage of
sonographers around the globe, innovations like the Vscan Air SL
with Caption AI are hugely transformative in cardiac care,
supporting rapid and confident assessments at the point of care,"
said cardiologist Jordan B. Strom, M.D., MSc. "AI guidance has
enormous potential in ultrasound due to its ability to guide
experts and relatively new users in retrieving diagnostic-quality
information to make timely and accurate decisions and get patients
on the right path sooner."
Caption AI provides real-time visual guidance to prompt users on
probe movements and includes a quality meter to ensure the user
obtains the best possible images. Once an image is captured, the
AutoEF feature automatically calculates a left ventricular ejection
fraction (LVEF). In addition, users can efficiently scan with
AutoCapture and Save Best Clip features to capture the best quality
image from each view.
The ultraportable Vscan Air SL provides high levels of depth,
resolution and sensitivity in imaging performance with an
industry-leading single crystal transducer technology. The latest
integration of Caption AI builds on GE HealthCare’s history and
innovation in handheld ultrasound—having introduced the pioneering
Vscan in 2010 as the first color, pocket-sized ultrasound
device—and is helping to make next-generation ultrasound care
accessible to even more patients.
"The integration of Caption AI with the Vscan Air SL handheld
ultrasound opens an entirely new chapter for cardiac screening.
This technology empowers users with guidance and tools for high
quality ultrasound scans and supports earlier detection of cardiac
disease," said Roland Rott, president and CEO, Ultrasound, GE
HealthCare. "The strategic acquisition of Caption Health in 2023
continues to expand the capabilities of our products and solidifies
our leadership in ultrasound and the emerging artificial
intelligence landscape."
The launch of Vscan Air SL with Caption AI advances GE
HealthCare’s vision and efforts to strengthen precision care,
joining the approximately 60 AI-enabled medical device
authorizations from GE HealthCare in the United States – more than
any other medical device company. Of these, approximately 30 are
AI-enabled ultrasound innovations.
In addition to Vscan Air SL, GE HealthCare will also showcase
its suite of innovative products and solutions across the
cardiology care pathway at ACC 2024, including CardioVisio for
Atrial Fibrillation, a digital, patient-centric clinical decision
support tool, which includes the most recent ACC guidelines.
Telling the story of the heart with integrated cardiology
technology, the comprehensive portfolio of cardiovascular solutions
delivers across the full continuum of patient care from diagnosis
and treatment all the way through post-treatment monitoring.
The Vscan Air SL with Caption AI will be on display in booth
#2517. For more information, visit the Vscan Air website here.
About Vscan Air
GE HealthCare's Vscan Air offers two flexible, wireless,
dual-probe handheld ultrasound options: the Vscan Air SL, which
includes a sector-phased array transducer for rapid cardiac
assessments, and the Vscan Air CL, which includes a curved array
transducer for abdominal imaging, obstetric assessments, and more.
Uniquely, both models also include a linear array transducer
bringing shallow and deep scanning together on a single dual probe
device suitable for a wide range of assessments. Both models
provide a flexible, lightweight, wireless device that delivers
crystal clear images anytime, anywhere to help accelerate diagnoses
and treatment decisions. The Vscan Air SL now features Caption AI
technology, providing clinicians with real-time, step-by-step
guidance for confident cardiac assessments at the point of care.
The Vscan Air app, available on Android™ and iOS™ devices, allows
for the secure viewing of images on a mobile device so clinicians
can take Vscan Air with them to every patient.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global medical technology,
pharmaceutical diagnostics, and digital solutions innovator,
dedicated to providing integrated solutions, services, and data
analytics to make hospitals more efficient, clinicians more
effective, therapies more precise, and patients healthier and
happier. Serving patients and providers for more than 125 years, GE
HealthCare is advancing personalized, connected, and compassionate
care, while simplifying the patient’s journey across the care
pathway. Together our Imaging, Ultrasound, Patient Care Solutions,
and Pharmaceutical Diagnostics businesses help improve patient care
from diagnosis, to therapy, to monitoring. We are a $19.6 billion
business with approximately 51,000 colleagues working to create a
world where healthcare has no limits.
Follow us on LinkedIn, X (formerly Twitter), and Insights for
the latest news, or visit our website https://www.gehealthcare.com/
for more information.
_______________________________ 1 World Health Organization.
Cardiovascular diseases (CVDs). June 11, 2021. Available at:
https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).
Accessed April 2024.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240402698062/en/
Eric Tatro Media Contact GE HealthCare +1 312 459 6140
Eric.Tatro@gehealthcare.com
GE HealthCare Technologies (NASDAQ:GEHC)
Historical Stock Chart
From Sep 2024 to Oct 2024
GE HealthCare Technologies (NASDAQ:GEHC)
Historical Stock Chart
From Oct 2023 to Oct 2024